JP2013507926A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013507926A5 JP2013507926A5 JP2012534364A JP2012534364A JP2013507926A5 JP 2013507926 A5 JP2013507926 A5 JP 2013507926A5 JP 2012534364 A JP2012534364 A JP 2012534364A JP 2012534364 A JP2012534364 A JP 2012534364A JP 2013507926 A5 JP2013507926 A5 JP 2013507926A5
- Authority
- JP
- Japan
- Prior art keywords
- binding agent
- bispecific binding
- linker moiety
- igf
- erbb3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000011230 binding agent Substances 0.000 claims description 76
- 125000005647 linker group Chemical group 0.000 claims description 49
- 230000008685 targeting Effects 0.000 claims description 36
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 239000002246 antineoplastic agent Substances 0.000 claims description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 210000004881 tumor cell Anatomy 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 6
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 6
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 6
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 238000000554 physical therapy Methods 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 239000013638 trimer Substances 0.000 claims description 4
- 206010055113 Breast cancer metastatic Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 101100059511 Homo sapiens CD40LG gene Proteins 0.000 claims description 2
- 101000764535 Homo sapiens Lymphotoxin-alpha Proteins 0.000 claims description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 2
- 101000830565 Homo sapiens Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 claims description 2
- 101000830598 Homo sapiens Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 claims description 2
- 101000851434 Homo sapiens Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 claims description 2
- 101000830594 Homo sapiens Tumor necrosis factor ligand superfamily member 14 Proteins 0.000 claims description 2
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims description 2
- 108010073807 IgG Receptors Proteins 0.000 claims description 2
- 102000009490 IgG Receptors Human genes 0.000 claims description 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 2
- 208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000000539 dimer Substances 0.000 claims description 2
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical group C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960002584 gefitinib Drugs 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 239000000833 heterodimer Substances 0.000 claims description 2
- 239000000710 homodimer Substances 0.000 claims description 2
- 102000057041 human TNF Human genes 0.000 claims description 2
- 102000050320 human TNFRSF4 Human genes 0.000 claims description 2
- 102000044949 human TNFSF10 Human genes 0.000 claims description 2
- 102000058177 human TNFSF12 Human genes 0.000 claims description 2
- 102000050326 human TNFSF13B Human genes 0.000 claims description 2
- 102000051198 human TNFSF14 Human genes 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000005865 ionizing radiation Effects 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims description 2
- 108010068617 neonatal Fc receptor Proteins 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108020001580 protein domains Proteins 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 229960001603 tamoxifen Drugs 0.000 claims description 2
- 229960000575 trastuzumab Drugs 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 3
- 230000009870 specific binding Effects 0.000 claims 3
- 238000011319 anticancer therapy Methods 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
- 230000012010 growth Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25142609P | 2009-10-14 | 2009-10-14 | |
| US61/251,426 | 2009-10-14 | ||
| PCT/US2010/052712 WO2011047180A1 (en) | 2009-10-14 | 2010-10-14 | Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013507926A JP2013507926A (ja) | 2013-03-07 |
| JP2013507926A5 true JP2013507926A5 (https=) | 2013-11-21 |
Family
ID=43511327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012534364A Pending JP2013507926A (ja) | 2009-10-14 | 2010-10-14 | ＩＧＦ−１Ｒ及びＥｒｂＢ３シグナル伝達を標的とする二重特異的結合剤及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20120244163A1 (https=) |
| EP (1) | EP2488199A1 (https=) |
| JP (1) | JP2013507926A (https=) |
| AU (1) | AU2010306774A1 (https=) |
| CA (1) | CA2777242A1 (https=) |
| WO (1) | WO2011047180A1 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2792327C (en) | 2010-03-11 | 2019-09-24 | Merrimack Pharmaceuticals, Inc. | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| EP4234698A3 (en) | 2010-05-06 | 2023-11-08 | Novartis AG | Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies |
| KR20130066631A (ko) | 2010-05-06 | 2013-06-20 | 노파르티스 아게 | 치료적 저밀도 지단백질-관련 단백질 ６ （ｌｒｐ６） 다가 항체에 대한 조성물 및 사용 방법 |
| BR112012029611A2 (pt) | 2010-05-21 | 2017-07-25 | Merrimack Pharmaceuticals Inc | proteína de fusão biespecífica, composição farmacêutica, método de tratamento de dano ao tecido em um indivíduo, método de promoção da regeração ou sobrevivência do tecido em um indivíduo e molécula de ácido nucleico |
| NZ607337A (en) | 2010-08-20 | 2015-06-26 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| AU2012222833B2 (en) | 2011-03-03 | 2017-03-16 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
| US20140134170A1 (en) * | 2011-03-11 | 2014-05-15 | Merrimack Pharmaceuticals, Inc. | Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers |
| CN105884900A (zh) * | 2011-04-19 | 2016-08-24 | 梅里麦克制药股份有限公司 | 单特异性和双特异性抗igf-1r和抗erbb3抗体 |
| US10344050B2 (en) * | 2011-10-27 | 2019-07-09 | Genmab A/S | Production of heterodimeric proteins |
| CN104039830A (zh) | 2011-11-04 | 2014-09-10 | 诺华股份有限公司 | 低密度脂蛋白相关蛋白6(lrp6)-半寿期延长物构建体 |
| KR102057742B1 (ko) | 2011-11-17 | 2019-12-19 | 군드람 정 | 의학적 용도를 위한 이중특이성 항체 |
| JP6180425B2 (ja) | 2011-11-23 | 2017-08-23 | メディミューン，エルエルシー | Ｈｅｒ３に特異的な結合分子及びそれらの使用 |
| LT2794658T (lt) * | 2011-12-19 | 2017-05-10 | Synimmune Gmbh | Bispecifinė antikūno molekulė |
| US20130165638A1 (en) * | 2011-12-27 | 2013-06-27 | Development Center For Biotechnology | Light chain-bridged bispecific antibody |
| BR112014024494A2 (pt) * | 2012-04-02 | 2017-08-08 | Merrimack Pharmaceuticals Inc | dosagem e administração de anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos |
| CN104768571B (zh) | 2012-07-13 | 2018-11-09 | 酵活有限公司 | 多价异多聚体支架设计和构建体 |
| WO2014037373A1 (en) * | 2012-09-07 | 2014-03-13 | Sanofi | Fusion proteins for treating a metabolic syndrome |
| ES2649991T3 (es) * | 2012-11-19 | 2018-01-16 | Baliopharm Ag | Anticuerpo biespecífico recombinante que se une a CD20 y CD95 |
| US11305012B2 (en) | 2013-09-24 | 2022-04-19 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
| EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| CA2975829A1 (en) * | 2014-02-20 | 2015-09-03 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith |
| US10745490B2 (en) | 2014-04-11 | 2020-08-18 | Celldex Therapeutics, Inc. | Anti-ErbB antibodies and methods of use thereof |
| EP3303398A1 (en) | 2015-05-29 | 2018-04-11 | Merrimack Pharmaceuticals, Inc. | Combination cancer therapies |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| CN115960249A (zh) | 2015-10-02 | 2023-04-14 | 银溪制药股份有限公司 | 用于组织修复的双特异性治疗性蛋白质 |
| JP2018536682A (ja) | 2015-12-11 | 2018-12-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｅｇｆｒ及び／またはｅｒｂｂ３遮断に耐性のある腫瘍の成長を低減または防止するための方法 |
| PE20190168A1 (es) * | 2016-03-24 | 2019-02-01 | Bayer Pharma AG | Complejos radiofarmaceuticos |
| US10723857B1 (en) * | 2016-04-15 | 2020-07-28 | United States Of America As Represented By The Administrator Of National Aeronautics And Space Administration | Polyimide aerogels with reduced shrinkage from isothermal aging |
| KR20240074000A (ko) | 2017-02-28 | 2024-05-27 | 다이이찌 산쿄 가부시키가이샤 | 항 her3 항체-약물 콘주게이트 투여에 의한 egfr-tki 저항성의 비소세포 폐암의 치료 방법 |
| WO2018219301A1 (zh) * | 2017-05-31 | 2018-12-06 | 四川大学华西医院 | 一种PDGFRβ靶向性肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途 |
| JP7551500B2 (ja) * | 2018-04-04 | 2024-09-17 | バイスクルテクス・リミテッド | ヘテロタンデム二環式ペプチド複合体 |
| KR20210062005A (ko) | 2018-09-20 | 2021-05-28 | 다이이찌 산쿄 가부시키가이샤 | 항 her3 항체-약물 콘쥬게이트 투여에 의한 her3 변이암의 치료 |
| JP2022514618A (ja) * | 2018-12-21 | 2022-02-14 | バイスクルテクス・リミテッド | Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド |
| WO2021013068A1 (en) * | 2019-07-19 | 2021-01-28 | Wuxi Biologics (Shanghai) Co., Ltd. | Polypeptide complex for conjugation and use thereof |
| US20240150484A1 (en) * | 2021-03-12 | 2024-05-09 | Genmab A/S | Non-activating antibody variants |
| WO2024248123A1 (ja) | 2023-06-02 | 2024-12-05 | 第一三共株式会社 | 抗ｈｅｒ３抗体－薬物コンジュゲートとｒａｓｇ１２ｃ阻害剤の組み合わせ |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| CA2453662A1 (en) | 2001-07-19 | 2003-01-30 | Stefan Ewert | Modification of human variable domains |
| AU2006247039B2 (en) | 2005-05-19 | 2011-03-03 | Amgen Inc. | Compositions and methods for increasing the stability of antibodies |
| KR101516823B1 (ko) | 2006-03-17 | 2015-05-07 | 바이오겐 아이덱 엠에이 인코포레이티드 | 안정화된 폴리펩티드 조성물 |
| SG178789A1 (en) | 2007-02-16 | 2012-03-29 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| MX2009012343A (es) * | 2007-05-14 | 2010-02-10 | Biogen Idec Inc | Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello. |
| KR20100058509A (ko) * | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
| KR20090014471A (ko) | 2007-08-06 | 2009-02-11 | 삼성전자주식회사 | 잉크젯 화상형성장치 |
| CA2721093A1 (en) * | 2008-04-11 | 2009-10-15 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| CN105884900A (zh) * | 2011-04-19 | 2016-08-24 | 梅里麦克制药股份有限公司 | 单特异性和双特异性抗igf-1r和抗erbb3抗体 |
-
2010
- 2010-10-14 CA CA2777242A patent/CA2777242A1/en not_active Abandoned
- 2010-10-14 AU AU2010306774A patent/AU2010306774A1/en not_active Abandoned
- 2010-10-14 JP JP2012534364A patent/JP2013507926A/ja active Pending
- 2010-10-14 WO PCT/US2010/052712 patent/WO2011047180A1/en not_active Ceased
- 2010-10-14 EP EP10775965A patent/EP2488199A1/en not_active Ceased
-
2012
- 2012-04-10 US US13/443,660 patent/US20120244163A1/en not_active Abandoned
-
2016
- 2016-12-07 US US15/371,536 patent/US20170210809A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013507926A5 (https=) | ||
| Gandullo-Sánchez et al. | HER3 in cancer: from the bench to the bedside | |
| US20250127858A1 (en) | Novel cytokine prodrugs | |
| US10428149B2 (en) | Single-chain tumor necrosis factor (TNF) ligand family molecules, fusion proteins and derivatives thereof | |
| BR112021005907A2 (pt) | citocinas mascaradas, ácido nucleico, vetor, célula hospedeira, métodos para produzir uma citocina mascarada, para tratar ou prevenir uma doença neoplásica e para tratar ou prevenir uma doença inflamatória ou autoimune neoplásica, composição, composição farmacêutica e kit | |
| JP2020501531A5 (https=) | ||
| JP2016520586A5 (https=) | ||
| CN112111008A (zh) | 抗cd73抗体及其应用 | |
| RS62151B1 (sr) | Konstrukti koji sadrže sirp-alfa domen ili njegovu varijantu | |
| JP7097293B2 (ja) | ヒトＦｃ受容体に結合する融合タンパク質 | |
| CN108463245A (zh) | 具有修饰的j链的结合分子 | |
| JP2020503860A (ja) | 免疫応答のコンディショナルアゴニスト | |
| JP2018501211A5 (https=) | ||
| US20250223347A1 (en) | Antigen binding constructs targeting her2 and uses thereof | |
| WO2020068774A1 (en) | System and method for the development of cd30 bispecific antibodies for immunotherapy of cd30+ malignancies | |
| EP4405379A1 (en) | Composition of recombinant antigen binding molecules and method of making and using thereof | |
| WO2021110990A1 (en) | Anti-clec-1a antibodies and antigen-binding fragment thereof | |
| WO2024078479A1 (zh) | 一种异源二聚体融合蛋白及其应用 | |
| CN103172741B (zh) | 全人源抗egfr抗体 | |
| Bakherad et al. | Engineering an anti-granulocyte colony stimulating factor receptor nanobody for improved affinity | |
| WO2024193705A1 (en) | Tnf superfamily member immunocytokine and uses thereof | |
| CN118139884A (zh) | 人源化抗clec-1a抗体和其抗原结合片段及其模拟物 | |
| WO2021244553A1 (zh) | 一种抗pd-l1和egfr的四价双特异性抗体 | |
| RU2844389C2 (ru) | Her2-нацеленные антигенсвязывающие конструкции и их использование | |
| WO2012024659A2 (en) | Antibody-based constructs directed against tyrosine kinase receptors |